Select eye drops under the Systane brand were voluntarily ... foreign material in a sealed single-use vial of the eye drop solution, according to the recall announcement. The company determined ...
In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...
Oculis' main value driver appears to be OCS-01, which targets a respectable $4B DME TAM with its non-invasive eye drops. See ...
The Healthy on MSN13d
More Eye Drops Have Been Recalled NationwideThe product may be used to treat a condition that the American Academy of Ophthalmology says affects around 20 million ...
The global ophthalmic sprays market, valued at USD 343 million in 2023, is projected to experience exponential growth, ...
About XDEMVY ® XDEMVY (lotilaner ophthalmic solution, 0.25%), formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root ...
What’s Causing National Vision Holdings Inc (EYE) Stock’s -20.88% Drop Over the Last Six Months?
National Vision Holdings Inc (EYE) stock saw a modest uptick, ending the day at $10.8 which represents a slight increase of $0.05 or 0.47% from the prior close of $10.75. The stock opened at $11 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback